Loading...

Sima Porten, MD, MPH

Title(s)Associate Professor, Urology
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-885-3695
ORCID ORCID Icon0000-0002-3948-4968 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco, CA2017Diversity, Equity, and Inclusion Champion Training

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer. Cancer Med. 2020 Sep 01. Washington SL, Gregorich SE, Meng MV, Suskind AM, Porten SP. PMID: 32869516.
      View in: PubMed   Mentions:    Fields:    
    2. Assessing Contemporary Trends in Female Speakership within Urologic Oncology. Urology. 2020 Aug 13. Talwar R, Bernstein A, Jones A, Crook J, Apolo AB, Taylor JM, Burke LM, Plimack ER, Porten SP, Greene KL, Psutka SP, Smith AB. PMID: 32798517.
      View in: PubMed   Mentions:    Fields:    
    3. Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database. World J Urol. 2020 Jul 31. de la Calle CM, Washington SL, Lonergan PE, Meng MV, Porten SP. PMID: 32737581.
      View in: PubMed   Mentions:    Fields:    
    4. Correction to: A comparison of stage-specific all-cause mortality between testicular sex cordstromal tumors and germ cell tumors: results from the National Cancer Database. BMC Urol. 2020 Jul 17; 20(1):103. Zuniga KB, Washington SL, Porten SP, Meng MV. PMID: 32680507.
      View in: PubMed   Mentions:    Fields:    
    5. Using provider-focused education toolkits can aid enhanced recovery programs to further reduce patient exposure to opioids. Perioper Med (Lond). 2020; 9:21. Sarin A, Lancaster E, Chen LL, Porten S, Chen LM, Lager J, Wick E. PMID: 32670568.
      View in: PubMed   Mentions:
    6. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 Jun 25; 181(7):1612-1625.e13. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. PMID: 32497499.
      View in: PubMed   Mentions:    Fields:    
    7. Reply by Authors. J Urol. 2020 Aug; 204(2):246. de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA. PMID: 32459975.
      View in: PubMed   Mentions:    Fields:    
    8. A comparison of stage-specific all-cause mortality between testicular sex cord stromal tumors and germ cell tumors: results from the National Cancer Database. BMC Urol. 2020 Apr 17; 20(1):40. Zuniga KB, Washington SL, Porten SP, Meng MV. PMID: 32303266.
      View in: PubMed   Mentions: 1     Fields:    
    9. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Eur Urol Oncol. 2020 Aug; 3(4):420-423. de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP. PMID: 32205136.
      View in: PubMed   Mentions: 1     Fields:    
    10. TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. Mol Cancer Res. 2020 Jun; 18(6):811-821. Mokkapati S, Porten SP, Narayan VM, Lim AH, Jayaratna IS, Roth B, Cheng T, Navai N, Wszolek M, Melquist J, Manyam G, Choi W, Broom B, Pretzsch S, Czerniak B, McConkey DJ, Dinney CPN. PMID: 32122956.
      View in: PubMed   Mentions:    Fields:    
    11. A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging. J Urol. 2020 08; 204(2):239-246. de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA. PMID: 32074006.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol. 2020 Feb 11; 20(1):12. Koya M, Osborne S, Chemaslé C, Porten S, Schuckman A, Kennedy-Smith A. PMID: 32046687.
      View in: PubMed   Mentions: 1     Fields:    
    13. Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer. Urol Clin North Am. 2020 Feb; 47(1):111-118. Chu CE, Porten SP, Grossfeld GD, Meng MV. PMID: 31757294.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    14. Promotion Disparities in Academic Urology. Urology. 2020 Apr; 138:16-23. Breyer BN, Butler C, Fang R, Meeks W, Porten SP, North AC, Anger JT. PMID: 31917291.
      View in: PubMed   Mentions:    Fields:    
    15. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 Feb 15; 26(4):882-891. Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. PMID: 31712383.
      View in: PubMed   Mentions: 3     Fields:    
    16. Gender differences in oncologic and functional outcomes in patients with bladder cancer undergoing radical cystectomy with urinary diversion. Curr Opin Urol. 2019 09; 29(5):542-547. Sadighian M, Porten S. PMID: 31313715.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Optimizing cystectomy outcomes. Cancer. 2019 10 15; 125(20):3502-3503. Porten SP, Master VA. PMID: 31299088.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol. 2019 08; 76(2):238-243. Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y. PMID: 31103391.
      View in: PubMed   Mentions:    Fields:    
    19. Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer. Cancer Epidemiol Biomarkers Prev. 2019 08; 28(8):1339-1344. Washington SL, Neuhaus J, Meng MV, Porten SP. PMID: 31092404.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur Urol. 2019 08; 76(2):200-206. Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA. PMID: 31092337.
      View in: PubMed   Mentions: 2     Fields:    
    21. The Association Between Race and Frailty in Older Adults Presenting to a Nononcologic Urology Practice. Urology. 2019 05; 127:19-23. Washington SL, Porten SP, Quanstrom K, Jin C, Bridge M, Finlayson E, Walter LC, Suskind AM. PMID: 30822479.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. Clin Genitourin Cancer. 2019 06; 17(3):e461-e471. Balakrishnan AS, Washington SL, Meng MV, Porten SP. PMID: 30799130.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Epigenetic Alterations in Bladder Cancer. Curr Urol Rep. 2018 Oct 24; 19(12):102. Porten SP. PMID: 30357502.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    24. Unraveling Associations Between Occupation and Bladder Cancer Aggressiveness: Describing the Landscape. Eur Urol Focus. 2018 09; 4(5):731-732. Psutka SP, Porten S. PMID: 30154044.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Do Women Work Less Than Men in Urology: Data From the American Urological Association Census. Urology. 2018 Aug; 118:71-75. Porten SP, Gaither TW, Greene KL, Baradaran N, Anger JT, Breyer BN. PMID: 29723591.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clin Epigenetics. 2018; 10:19. Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP. PMID: 29456764.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    27. Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors. PLoS One. 2017; 12(11):e0187975. Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP. PMID: 29140994.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    28. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer. 2017 Dec 01; 123(23):4574-4582. Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP. PMID: 28881475.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget. 2017 May 23; 8(21):34205-34222. Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C. PMID: 27494900.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    30. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018 09; 4(5):720-724. Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB. PMID: 28753837.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    31. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):78-86. Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP. PMID: 27511849.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    32. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015 Oct-Dec; 31(4):297-303. Porten SP, Leapman MS, Greene KL. PMID: 26604440.
      View in: PubMed   Mentions:
    33. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. PMID: 26343003.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsCTClinical Trials
    34. Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison. PLoS One. 2015; 10(8):e0137141. Sanford T, Porten S, Meng MV. PMID: 26317352.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    35. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes. J Urol. 2015 Jul; 194(1):85-90. Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR. PMID: 25623742.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    36. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):517-23. Porten SP, Willis D, Kamat AM. PMID: 24921905.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    37. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):246-51. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR. PMID: 24819235.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    38. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. PMID: 24633966.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    39. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. PMID: 24525232.
      View in: PubMed   Mentions: 315     Fields:    Translation:Humans
    40. Xanthogranulomatous pyelonephritis presenting with a left flank mass. Case Rep Med. 2013; 2013:362194. Zaid UB, Porten SP, Cinman NM, Sanford TH, Breyer BN. PMID: 24367381.
      View in: PubMed   Mentions:
    41. Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol. 2014 Feb; 65(2):267-9. Kamat AM, Porten S. PMID: 24199712.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    42. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol. 2013 Sep; 23(5):435-43. Willis DL, Porten SP, Kamat AM. PMID: 23880739.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    43. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. PMID: 23911605.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    44. Gunshot wounds to the lower urinary tract: a single-institution experience. J Trauma Acute Care Surg. 2013 Mar; 74(3):725-30; discussion 730-1. Cinman NM, McAninch JW, Porten SP, Myers JB, Blaschko SD, Bagga HS, Breyer BN. PMID: 23425728.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    45. The role of active surveillance in the management of prostate cancer. J Natl Compr Canc Netw. 2013 Feb 01; 11(2):183-7. Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. PMID: 23411385.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. Active surveillance: does serial prostate biopsy increase histological inflammation? Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):165-9. Glass AS, Porten SP, Bonham M, Tran TC, Cowan JE, Punnen S, Chan JM, Carroll PR. PMID: 23318528.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    47. High-risk nonmuscle invasive bladder cancer: definition and epidemiology. Curr Opin Urol. 2012 Sep; 22(5):385-9. Porten SP, Cooperberg MR. PMID: 22842681.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Commentary on refractory ischemic priapism. Transl Androl Urol. 2012 Mar; 1(1):61-5. Garcia M, Porten S, Lue TF. PMID: 26813294.
      View in: PubMed   Mentions:
    49. Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer. J Urol. 2011 Nov; 186(5):1825-9. Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR. PMID: 21944082.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    50. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. PMID: 21632511.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    51. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol. 2013 May; 31(4):442-7. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. PMID: 21478037.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    52. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. PMID: 21419438.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansPHPublic Health
    53. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011 Jun; 29(3):265-71. Porten SP, Cooperberg MR, Konety BR, Carroll PR. PMID: 21347810.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    54. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease. Nat Rev Urol. 2011 Mar; 8(3):124-5. Whitson JM, Porten SP, Carroll PR. PMID: 21304508.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    55. The outcomes of perineal urethrostomy with preservation of the dorsal urethral plate and urethral blood supply. Urology. 2011 May; 77(5):1223-7. Myers JB, Porten SP, McAninch JW. PMID: 21215434.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    56. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. PMID: 21115873.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    57. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010 Nov; 184(5):1931-6. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. PMID: 20846693.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    58. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol. 2010 Jun; 183(6):2244-8. Eisner BH, Porten SP, Bechis SK, Stoller ML. PMID: 20400141.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    59. The role of race in determining 24-hour urine composition in white and Asian/Pacific Islander stone formers. J Urol. 2010 Apr; 183(4):1407-11. Eisner BH, Porten SP, Bechis SK, Stoller ML. PMID: 20171692.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    60. Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis. J Urol. 2010 Feb; 183(2):576-9. Eisner BH, Porten SP, Bechis SK, Stoller ML. PMID: 20018328.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    61. Prevalence and severity of undiagnosed urinary incontinence in women. Am J Med. 2009 Nov; 122(11):1037-42. Wallner LP, Porten S, Meenan RT, O'Keefe Rosetti MC, Calhoun EA, Sarma AV, Clemens JQ. PMID: 19854332.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    62. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2010 Feb; 105(4):472-5. Porten SP, Cooperberg MR, Carroll PR. PMID: 19681901.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    63. Diagnosis of female diverticula using magnetic resonance imaging. Adv Urol. 2008; 213516. Porten S, Kielb S. PMID: 18604291.
      View in: PubMed   Mentions:
    64. Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes. J Urol. 2007 Oct; 178(4 Pt 2):1758-61; discussion 1762. Diaz Saldano D, Chaviano AH, Maizels M, Yerkes EB, Cheng EY, Losavio J, Porten SP, Sullivan C, Zebold KF, Hagerty J, Kaplan WE. PMID: 17707433.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. Math5 is required for both early retinal neuron differentiation and cell cycle progression. Dev Biol. 2006 Jul 15; 295(2):764-78. Le TT, Wroblewski E, Patel S, Riesenberg AN, Brown NL. PMID: 16690048.
      View in: PubMed   Mentions: 51     Fields:    Translation:AnimalsCells
    66. Math5 is required for retinal ganglion cell and optic nerve formation. Development. 2001 Jul; 128(13):2497-508. Brown NL, Patel S, Brzezinski J, Glaser T. PMID: 11493566.
      View in: PubMed   Mentions: 179     Fields:    Translation:AnimalsCells
    Sima's Networks
    Concepts (238)
    Derived automatically from this person's publications.
    _
    Co-Authors (46)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _